The broadening spectrum of mitochondrial disease: Shifts in the diagnostic paradigm

被引:48
作者
Liang, Christina [1 ]
Ahmad, Kate [1 ]
Sue, Carolyn M. [1 ,2 ,3 ]
机构
[1] Royal N Shore Hosp, Dept Neurol, St Leonards, NSW 2065, Australia
[2] Royal N Shore Hosp, Kolling Inst Med Res, Dept Neurogenet, St Leonards, NSW 2065, Australia
[3] Univ Sydney, St Leonards, NSW 2065, Australia
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS | 2014年 / 1840卷 / 04期
关键词
Mitochondrial disease; FGF21; Next-generation-sequencing; RESPIRATORY-CHAIN DISORDERS; TRANSFER RNALEU(UUR) GENE; A3243G POINT MUTATION; STROKE-LIKE EPISODES; RAGGED-RED FIBERS; LACTIC-ACIDOSIS; MELAS SYNDROME; DNA MUTATIONS; PREVALENCE; CHILDREN;
D O I
10.1016/j.bbagen.2013.10.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Background: The diagnosis of mitochondrial disease requires a complex synthesis of clinical, biochemical, histological, and genetic investigations. An expanding number of mitochondrial diseases are being recognized, despite their phenotypic diversity, largely due to improvements in methods to detect mutations in affected individuals and the discovery of genes contributing to mitochondrial function. Improved understanding of the investigational pitfalls and the development of new laboratory methodologies that lead to a molecular diagnosis have necessitated the field to rapidly adopt changes to its diagnostic approach. Scope of review: We review the clinical, investigational and genetic challenges that have resulted in shifts to the way we define and diagnose mitochondrial disease. Incorporation of changes, including the use of fibroblast growth factor 21 (FGF-21) and next generation sequencing techniques, may allow affected patients access to earlier molecular diagnosis and management. Major conclusions: There have been important shifts in the diagnostic paradigm for mitochondrial disease. Diagnosis of mitochondrial disease is no longer reliant on muscle biopsy alone, but should include clinical assessment accompanied by the use of serological biomarkers and genetic analysis. Because affected patients will be defined on a molecular basis, oligosymptomatic mutation carriers should be included in the spectrum of mitochondrial disease. Use of new techniques such as the measurement of serum FGF-21 levels and next-generation-sequencing protocols should simplify the diagnosis of mitochondrial disease. General significance: Improvements in the diagnostic pathway for mitochondrial disease will result in earlier, cheaper and more accurate methods to identify patients with mitochondrial disease. This article is part of a Special Issue entitled Frontiers of Mitochondrial Research. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1360 / 1367
页数:8
相关论文
共 54 条
[1]
Diagnostic criteria for respiratory chain disorders in adults and children [J].
Bernier, FP ;
Boneh, A ;
Dennett, X ;
Chow, CW ;
Cleary, MA ;
Thorburn, DR .
NEUROLOGY, 2002, 59 (09) :1406-1411
[2]
Brinjikji W, 2011, JIMD REP, V1, P89, DOI 10.1007/8904_2011_22
[3]
Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing [J].
Calvo, Sarah E. ;
Compton, Alison G. ;
Hershman, Steven G. ;
Lim, Sze Chern ;
Lieber, Daniel S. ;
Tucker, Elena J. ;
Laskowski, Adrienne ;
Garone, Caterina ;
Liu, Shangtao ;
Jaffe, David B. ;
Christodoulou, John ;
Fletcher, Janice M. ;
Bruno, Damien L. ;
Goldblatt, Jack ;
DiMauro, Salvatore ;
Thorburn, David R. ;
Mootha, Vamsi K. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (118)
[4]
Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO
[5]
2-G
[6]
MELAS - CLINICAL-FEATURES, BIOCHEMISTRY, AND MOLECULAR-GENETICS [J].
CIAFALONI, E ;
RICCI, E ;
SHANSKE, S ;
MORAES, CT ;
SILVESTRI, G ;
HIRANO, M ;
SIMONETTI, S ;
ANGELINI, C ;
DONATI, MA ;
GARCIA, C ;
MARTINUZZI, A ;
MOSEWICH, R ;
SERVIDEI, S ;
ZAMMARCHI, E ;
BONILLA, E ;
DEVIVO, DC ;
ROWLAND, LP ;
SCHON, EA ;
DIMAURO, S .
ANNALS OF NEUROLOGY, 1992, 31 (04) :391-398
[7]
MITOCHONDRIAL ENCEPHALOMYOPATHY - VARIABLE CLINICAL EXPRESSION WITHIN A SINGLE KINDRED [J].
CRIMMINS, D ;
MORRIS, JGL ;
WALKER, GL ;
SUE, CM ;
BYRNE, E ;
STEVENS, S ;
JEANFRANCIS, B ;
YIANNIKAS, C ;
PAMPHLETT, R .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1993, 56 (08) :900-905
[8]
Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial disease [J].
Davis, Ryan L. ;
Liang, Christina ;
Edema-Hildebrand, Fabienne ;
Riley, Catherine ;
Needham, Merrilee ;
Sue, Carolyn M. .
NEUROLOGY, 2013, 81 (21) :1819-1826
[9]
Pathogenic mitochondrial DNA mutations are common in the general population [J].
Elliott, Hannah R. ;
Samuels, David C. ;
Eden, James A. ;
Relton, Caroline L. ;
Chinnery, Patrick F. .
AMERICAN JOURNAL OF HUMAN GENETICS, 2008, 83 (02) :254-260
[10]
EFNS guidelines on the molecular diagnosis of mitochondrial disorders [J].
Finsterer, J. ;
Harbo, H. F. ;
Baets, J. ;
Van Broeckhoven, C. ;
Di Donato, S. ;
Fontaine, B. ;
De Jonghe, P. ;
Lossos, A. ;
Lynch, T. ;
Mariotti, C. ;
Schoels, L. ;
Spinazzola, A. ;
Szolnoki, Z. ;
Tabrizi, S. J. ;
Tallaksen, C. M. E. ;
Zeviani, M. ;
Burgunder, J. -M. ;
Gasser, T. .
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (12) :1255-1264